Table 1.
Validation set clinical features grouped according to immune-adaptive and immune innate prevalent states
| Variable | Overall N:431 | Immune adaptive prevalent N: 215 | Immune innate prevalent N:216 | P |
| Age (years), median [IQR] | 61.0 [49.0–74.0] | 61.0 [47.0–71.5] | 62.0 [50.0–75.5] | 0.125 |
| Male, n (%) | 240 (55.8) | 119 (55.3) | 121 (56.3) | 0.923 |
| Heart rate (bpm), mean (SD) | 109.8 (24.7) | 109.4 (23.9) | 110.4 (25.8) | 0.785 |
| Temperature (oC), median [IQR] | 37.7 [36.8–38.8] | 37.5 [36.7–38.6] | 37.8 [37.1–38.9] | 0.177 |
| MAP (mmHg), mean (SD) | 75.6 (18.0) | 78.3 (17.7) | 72.4 (17.9) | 0.026 |
| WBC (×103), median [IQR] | 14.2 [9.4–20.7] | 12.9 [9.0–18.4] | 15.3 [9.9–22.9] | 0.037 |
| Lymphocytes (cells), median [IQR] | 950.0 [516.0–1587.0] | 1195.3 [681.8–1781.5] | 600.0 [357.2–1292.5] | <0.001 |
| Lymphopenia, n (%) | 76 (48.1) | 30 (34.9) | 46 (63.9) | 0.001 |
| Platelets (×103), median [IQR] | 189.0 [123.0–258.0] | 198.0 [131.0–288.0] | 179.0 [102.5–232.5] | 0.030 |
| INR, median [IQR] | 1.3 [1.2–1.6] | 1.3 [1.1–1.5] | 1.4 [1.2–1.7] | 0.054 |
| Coagulation disorder, n (%) | 17 (23.6) | 7 (16.7) | 10 (33.3) | 0.174 |
| Shock, n (%) | 197 (54.0) | 85 (45.2) | 112 (63.3) | 0.001 |
| SOFA, mean (SD) | 6.2 (3.2) | 5.2 (2.8) | 7.3 (3.3) | <0.001 |
| APACHE II, mean (SD) | 22.1 (8.8) | 20.4 (8.9) | 24.1 (8.2) | <0.001 |
| Count of Organ Failures, median [IQR] | 2.0 [0.5–2.0] | 1.0 [0.0–1.0] | 2.0 [1.0–3.0] | 0.001 |
| Hospital LOS (days), median [IQR] | 8.5 [4.2 0–15.0] | 8.0 [4.0–12.0] | 11.0 [5.0–18.0] | 0.021 |
| Non-survivor, n (%) | 124 (28.8) | 48 (22.3) | 76 (35.2) | 0.004 |
APACHE II score, Acute Physiology and Chronic Health Evaluation; coagulation disorder, Platelet < 100,000 and INR > 1.3; IQR, Interquartile range; LOS, length of stay; lymphopenia, lymphocytes ≤ 900 cells; MAP, Mean arterial blood pressure; SD, standard deviation; SOFA score, Sequential Organ Failure Assessment; WBC, white blood cell.